|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.03.26 - 22:18
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise price of $33.96 per share, which is equal to the closing price of Stoke's common stock on March 16, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/4...
|
|
|
|
|
|
|
|
|
|
|
18.02.26 - 22:06
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on February 17, 2026, it granted stock options to purchase an aggregate of 22,950 shares of common stock to five new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise price of $31.09 per share, which is equal to the closing price of Stoke's common stock on February 17, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate...
|
|
|
|
|
|
|
16.01.26 - 22:03
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
|
|
|
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise price of $29.28 per share, which is equal to the closing price of Stoke's common stock on January 15, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate o...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
